English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/60179
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response

AuthorsSánchez-Guijo, Fermín M.; Hernández, Jesús M. ; Lumbreras, Eva ; Morais, Patricia; Santamaría, Carlos; García, Juan L. ; Gutiérrez, Norma Carmen; San Miguel, Jesús F. ; Cañizo, María Consuelo del
Issue Date2009
CitationLeukemia Research 33(1): 170-173 (2009)
AbstractInformation on the effects of imatinib mesylate (IM) on the non-clonal bone marrow (BM) cell compartment is scanty. We have analyzed the gene expression profile of BM hematopoietic cells after IM therapy in 20 patients with chronic myeloid leukaemia (CML) in complete cytogenetic response (CCyR) and compared it with that of normal volunteer donors by oligonucleotide microarrays. In CCyR CML samples, IM induces a decrease in proliferation as well as increase in apoptosis and ubiquitination in residual non-clonal BM cells. In addition, IM diminishes cell-to-cell adhesion and downregulates the expression of the erythropoietin (EPO) receptor gene. The latter was confirmed by RT-PCR. © 2008 Elsevier Ltd. All rights reserved.
Identifiersdoi: 10.1016/j.leukres.2008.07.014
issn: 0145-2126
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.